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Andrew B. Gilla, Nicholas McGlashana, Martin J. Gravesa, Markus Schwaigere,
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Dissolution dynamic nuclear polarization (DNP) enables the metabolism of hyperpolarized 13C-labelled molecules,
such as the conversion of [1-13C]pyruvate to [1-13C]lactate, to be dynamically and non-invasively imaged in tissue.
Imaging of this exchange reaction in animal models has been shown to detect early treatment response and corre-
late with tumour grade. The first human DNP study has recently been completed, and, for widespread clinical trans-
lation, simple and reliable methods are necessary to accurately probe the reaction in patients. However, there is
currently no consensus on the most appropriate method to quantify this exchange reaction. In this study, an
in vitro system was used to compare several kinetic models, as well as simple model-free methods. Experiments were
performed using a clinical hyperpolarizer, a human 3 T MR system, and spectroscopic imaging sequences. The quan-
titative methods were compared in vivo by using subcutaneous breast tumours in rats to examine the effect of
pyruvate inflow. The two-way kinetic model was the most accurate method for characterizing the exchange reaction
in vitro, and the incorporation of a Heaviside step inflow profile was best able to describe the in vivo data. The
lactate time-to-peak and the lactate-to-pyruvate area under the curve ratio were simple model-free approaches that
accurately represented the full reaction, with the time-to-peak method performing indistinguishably from the best
kinetic model. Finally, extracting data from a single pixel was a robust and reliable surrogate of the whole region of
interest. This work has identified appropriate quantitative methods for future work in the analysis of human
hyperpolarized 13C data. © 2016 The Authors. NMR in Biomedicine published by John Wiley & Sons Ltd.
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INTRODUCTION
Functional and molecular imaging is increasingly used as a rou-
tine clinical tool in many areas of oncology. The advent of molec-
ularly targeted drugs, combinational therapies, and personalized
medicine has resulted in an increasing requirement for specific
imaging methods to monitor drug efficacy; consequently, new
imaging methods to probe tumour biology are required that
demonstrate both intra- and inter-patient repeatability. Dissolu-
tion dynamic nuclear polarization (DNP) is a new imaging test,
which has the potential to image tissue biology. The technique
increases the signal-to-noise ratio (SNR) of molecules containing
one or more 13C nuclei by more than 10 000-fold above thermal
levels; this process is undertaken outside of the animal or
patient, and the hyperpolarized molecule is subsequently
injected intravenously (1). When combined with 13C-MRSI, this
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increase in SNR allows real-time in vivo metabolism of the mole-
cules to be imaged non-invasively (2).
There are now many 13C-labelled probes that have been suc-
cessfully hyperpolarized using DNP, and these have been used
to interrogate many aspects of tissue biology and metabolism
that occur in a wide range of disease processes (3–8). [1-13C]Py-
ruvate is the most extensively studied of these probes; the major
reaction of pyruvate is its conversion into [1-13C]lactate, which is
catalysed by the enzyme lactate dehydrogenase (LDH) and
requires the reduced form of nicotinamide adenine dinucleotide
(NADH) as a cofactor. Hyperpolarized [1-13C]pyruvate may also form
[1-13C]alanine, [1-13C]bicarbonate, and [1-13C]pyruvate-hydrate in a
pH-dependent reaction (9). These reactions have been well charac-
terized in vivo in pre-clinical animal models of disease (10–14) and
there are now a number of sites worldwide that are developing
the technique for human use (15).
The success of hyperpolarized 13C-labelled pyruvate as a can-
cer imaging biomarker is largely dependent on the phenomenon
of aerobic glycolysis within tumours known as the Warburg
effect (16). There is a high lactate concentration within most can-
cers, even in normoxic conditions, and the hyperpolarized 13C
signal may rapidly exchange between the injected [1-13C]pyru-
vate and the endogenous lactate pool. Imaging of this exchange
reaction in animal models has been shown to detect early treat-
ment response (17,18) and correlate with tumour grade (19). The
results from the only clinical study performed to date have
shown that labelled lactate may be present in small tumours that
are not visible with standard proton imaging techniques (15).
The sensitivity of 13C-MRSI to small changes in metabolic rate
offers the potential to non-invasively monitor metabolic alter-
ations in patients. However, for any novel imaging technique
to be widely adopted, it must be repeatable and reproducible,
and will ideally utilize simple and robust quantitative methods for
analysis. Current clinical approaches for the analysis of dynamic
contrast-enhanced (DCE) MRI and positron emission tomography
(PET) can offer insight into quantitative imaging with DNP. For
example, the maximum standardized uptake value (SUVmax) is a
very simple and powerful routine clinical tool to quantify metabo-
lism in PET imaging with 18F-fluorodeoxyglucose (20). For each
voxel of a PET image, the SUV is defined as the tissue radioactivity
concentration divided by the injected radiation per unit body
weight, correcting for decay from the time of injection. The SUVmax
is the voxel of highest SUV within a region of interest (ROI), while
the SUVmean is the average over that region. A number of methods
have been employed to quantify the pyruvate–lactate exchange
reaction measured using DNP, many of which involve fitting kinetic
models of varying complexity to imaging or spectroscopy data to
produce the forward reaction rate constant kP as a quantitative
marker (17,19,21,22). Simple methods for estimating kP from the
time course of pyruvate and lactate have been suggested (23), as
well as methods using model-free parameters such as the area
under the metabolite curve (AUC) (24), or ratios of the metabolite
signal peaks (25,26). However, there is currently no consensus on
the best method to characterize the pyruvate–lactate reaction,
either for research purposes or for more routine clinical use.
In this study,weusedboth in vitro and in vivodynamic hyperpolarized
data to comprehensively compare a range of kinetic models and simple
analysis parameters. We used a clinical hyperpolarizer and imaging
sequences with a 3 T MR system, as well as a pyruvate concentration
similar to the blood pyruvate concentration we anticipate in future
patient studies. Theaimwas todeterminewhichquantitativeparameters
aremost appropriate todescribe thedynamic time-coursedataacquired,
testing for accuracy, simplicity and robustness in each case. Each analysis
was also applied in vivo to rats with subcutaneous tumours, which were
imaged with the same spectroscopic imaging sequence to examine the
effect of pyruvate inflow.
MATERIALS AND METHODS
In vitro experiments
Research grade fluid paths (GE Healthcare, Milwaukee, WI, USA) were
filled with 100 μl of [1-13C]pyruvic acid dopedwith 15mMof an elec-
tron paramagnetic agent (trityl radical AH111501, GE Healthcare,
Milwaukee, WI, USA) and 30 ml of dissolution fluid containing
1 g l1 ethylenediaminetetraacetic acid (EDTA, GE Healthcare). Sam-
ples were polarized using a clinical hyperpolarizer (SPINlab, GE
Healthcare) at approximately 0.9 K and 5 T for an average of 101
min (range 83–149 min) to an average polarization of 21% (range
10–38%) at the time of measurement using a benchtop NMR polar-
imeter (Oxford Instruments, Abingdon, UK). Following rapid dissolu-
tion, 1.4ml of neutralizationmedium containing 0.72MNaOH, 0.4M
Tris buffer and 0.1 g l1 EDTA (GE Healthcare) was added to the so-
lution. The final pH ranged from 6.7 to 7.4 with an average of pH 7.2.
Imaging phantoms consisted of 15 ml Falcon tubes filled to 14
ml with fivefold concentrated phosphate buffered saline at pH 7.2
and containing the coenzyme NADH at 4.4 mM (Sigma-Aldrich,
Gillingham, UK). L-LDH from rabbit muscle (Sigma-Aldrich,
Gillingham, UK) was added in quantities varying from 0 to 120 U, a
range chosen to incorporate the expected range of kP in human
blood based on the only published study to date (mean ± standard
deviation (SD) of 0.045 ± 0.025 s1) (15). 1 ml of the above 60 mM
hyperpolarized solution was added simultaneously to the three
tubes making up each set immediately before imaging, giving a
final pyruvate concentration of about 4 mM. This is similar to the
final blood concentration in the rats (~3 mM) and that expected
in patients (~1.5 mM). If uniform distribution is achieved in the
body in the timescale of the half-life of hyperpolarization, then
the tissue concentrations would be lower. Neither pyruvate nor
NADH were rate limiting. The time between dissolution and
imaging was approximately 35 s.
In vivo experiments
Four adult female Fischer 344 rats (Charles River, Sulzfeld,
Germany; 165 ± 6 g body weight) bearing subcutaneous mam-
mary adenocarcinomas were imaged (27,28). Tumours were
induced by implanting 1 × 106 MAT B III cells (syngenic breast
cancer cell line), and imaging was performed 12–16 days after cell
implantation. Animals were anesthetized with 1–3% isoflurane,
monitored for ECG, breathing, and temperature, and kept warm
on a heating pad with circulating warm water. The time delay
between dissolution and injection was 15–20 s. The animal
study was approved by the local governmental committee for
animal protection and welfare (Tierschutzbehörde, Regierung
von Oberbayern).
[1-13C]Pyruvic acid doped with 15 mM of the trityl radical
OX063 and 1 mM gadoteric acid (Guerbet, Paris, France) was po-
larized in a HyperSense DNP polarizer (Oxford Instruments) for
approximately 45 min at 1.4 K and 3.35 T to a polarization of ap-
proximately 25%. Dissolution fluid, containing 80 mM NaOH,
80 mM Tris buffer, and 0.1 g l1 EDTA dissolved in water, was
heated to 185 °C and used to rapidly dissolve the polarized sam-
ple. The final solution contained 80 mM [1-13C]pyruvate at pH 7.6
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and physiological temperature and osmolarity. This was injected
into a tail vein inside the MRI scanner at a rate of approximately
0.2 ml s1 and at a dose of 2.5 ml kg1. Dynamic imaging was
performed from the time of injection.
Spectroscopic imaging
All imaging was carried out on a clinical 3 T MRI system (Signa
HDx, GE Healthcare) using imaging sequences from the Multinu-
clear Spectroscopy (MNS) research pack Version 2.0 (GE Global
Research, Munich, Germany). Enzyme phantoms were imaged
in sets of three using a 13C–1H multi-nuclear receive/transmit coil
(GE Coils, Aurora, OH, USA). First, four 90° non-localized spectral–
spatial pulses with TR = 1 s centred on the lactate Larmor fre-
quency were applied (27); this was found to be the optimum
number for removing signal from any lactate labelling prior to
commencement of the experiment whilst retaining maximum
pyruvate polarization. These were immediately followed by a 3
min IDEAL (iterative decomposition with echo asymmetry and
least-squares estimation) spiral chemical shift imaging (CSI)
acquisition (29) acquired using a single 20 mm axial slice. Each
excitation is followed by a single-shot spiral image encoding
module, with echo-time shifting of 1.12 ms between excitations.
Seven time-shifted echoes plus a single free induction decay
(FID) spectrum are acquired in total for each time step, with
the chemical-shift information from the FID providing prior
knowledge for the reconstruction. Other parameters were TR
500 ms, flip angle 5°, field of view (FOV) 80 mm, nominal matrix
resolution 32 × 32 and 4 s time resolution.
Animals were imaged on a similar clinical 3 T MRI system
(Signa HDx, GE Healthcare) using a rat-sized 13C–1H multi-
nuclear birdcage coil. The same IDEAL spiral CSI acquisition
was performed through four axial 10 mm slices over 1 min with
a temporal resolution of 4 s. 13C-pyruvate is replenished by
inflowing blood in vivo, so a larger flip angle of 10° was used.
All other parameters were consistent with the in vitro experi-
ments. Single metabolite k-space data was first reconstructed
by matrix inversion with off-resonance correction, followed by
Cartesian regridding for spatial reconstruction (29). Gaussian
k-space filtering was applied during post-processing on both
data sets, resulting in an effective image resolution of 5 × 5
mm2. For anatomical reference, standard gradient echo proton
images were acquired from the same slice geometry and FOV
(resolution 256 × 256, slice thickness 3 mm, spacing 7 mm, TE
10 ms, TR 500 ms).
Data analysis
Imaging data was exported into MATLAB (MathWorks, Natick,
MA, USA) for analysis using custom built software. Images were
partially noise-corrected by subtracting the average squared
background noise from the power images (30). Dynamic time-
course data for pyruvate and lactate were extracted from the
images, using two methods for comparison. In the first, an ROI
was defined by thresholding the t = 0 pyruvate image at 40%
of the maximum pyruvate signal within each phantom for the
in vitro data, or by outlining the tumour boundary based on
the anatomical proton image for the in vivo data. This ROI was
applied to all subsequent images in the series and the pixels
within the ROI were averaged to produce the relative signal
strengths of each metabolite at each time point. The second
method defined a pixel of interest (POI) as the pixel within each
phantom, or within the rat tumour, that demonstrated the highest
lactate signal after averaging over all time points. Dynamic data
from these two extraction methods was separately analysed using
each of the methods detailed below.
Kinetic modelling
The exchange reaction between pyruvate and lactate, along with
the irreversible hyperpolarized signal loss due to spin–lattice
relaxation and applied RF excitation, can be characterized by
the following coupled differential equations:
dP tð Þ
dt
¼ kLL tð Þ  kPP tð Þ  ρP tð Þ
dL tð Þ
dt
¼ kPP tð Þ  kLL tð Þ  ρL tð Þ
where P and L are the relative pyruvate and lactate signal
intensities, kP and kL are the forward and backward reaction rate








where T1 is the relaxation time of pyruvate in the medium or
tissue, tR is the known repetition time of the applied RF pulses
and θ is the flip angle. To reduce the number of parameters to
be fitted, we assume throughout that the pyruvate and lactate
relaxivities are equal, which in the limit of fast exchange
between metabolites can be shown to be a good approximation
(31), and use the above expression to correct for RF flip angle.
Each model variant was applied to yield the forward reaction
rate constant kP, the T1 decay constant, their standard errors
and other fitting parameters where appropriate. Constrained fits
were carried out in MATLAB using the fmincon function unless
otherwise stated. Solutions were found by minimizing the nega-
tive logarithm of the maximum likelihood function, which for N
data points is given by















þ ln Pi  Pdatai
 2Þ
Here K is the vector of free parameters to be fitted, σ2 is the
lactate variance, Li and Pi are the model estimates of the metab-
olite signal strengths and Li
data and Pi
data the measured values for
the ith data point. This likelihood function is derived from a
Bayesian extension to least squares minimization that addresses
the disproportionately large early pyruvate signal, as described
by Hill et al (24). It incorporates a lower-bound prior on the pyru-
vate noise, which acts to reduce the impact of any large early
pyruvate residuals which can otherwise dominate the fit. Due
to the sensitivity of the optimization algorithm to the initial
values of P and L, we used a Monte Carlo method to randomly
vary these inputs over 1000 runs for each model fit. Inputs were
allowed to vary over a Gaussian distribution centred, with an SD
of 5%, on the measured value of P or L at t = 0.
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The two-site exchange model
For the two-way differential model, the above set of differential
equations were solved simultaneously to fit the pyruvate and
lactate time-course data with kP, kL and ρ as free parameters.
The equations may also be solved analytically to give the
following solutions:
P tð Þ ¼ 1
kP þ kLfP 0ð Þ kLe
ρt þ kPe kPþkLþρð Þt
 
þL 0ð Þ kLeρt  kLe kPþkLþρð Þt
 
g
L tð Þ ¼ 1
kP þ kLfP 0ð Þ kPe
ρt  kPe kPþkLþρð Þt
 
þL 0ð Þ kPeρt þ kLe kPþkLþρð Þt
 
g
These equations themselves may then be fitted directly to the
data in the two-way integral model, which is computationally
faster than applying the full differential fit but may be more sen-
sitive to the initial values of the parameters. For the in vitro data,
the latter two models are virtually identical apart from the fitting
algorithms used; however, they require different approximations
for metabolite inflow when used in vivo. A popular simplification
of the model is to set the backward reaction rate constant kL to
zero (19,21,22,32,33). This is argued to be a reasonable assump-
tion, since kL is often around 1/10 of the forward rate constant
kP and, depending on the model used, may not be a mathema-
tically distinct parameter. To investigate the validity of the
one-way model, the above integral solutions with kL = 0 were also
applied to the data.
Ratiometric model
A ratiometric model has been suggested by Li et al (31). Briefly,
when the ratio is taken of the above integral solutions, ρ can
be eliminated as a parameter; this new model can be fitted to
the ratio of the lactate-to-pyruvate data to solve for the rate con-
stants kP and kL. Prior to fitting with the nlinfit function in
MATLAB, ratio data was smoothed by averaging over every three
data points. The lactate data was used to weight the fit towards
the region in which the rate constants are stable and ρ was sub-
sequently derived as a single unknown by inputting the kP and
kL obtained from the ratiometric fit into the differential kinetic
model.
Model-free methods
Fall minus rise at height α approach
Pagès and Kuchel suggest a method for estimating kP and ρ from
graphical features of the time course, which they call the FmRα
(fall minus rise at height α) approach (23). They suggest parame-
ter β to be the ratio of the lactate-to-pyruvate signals for the time
at which the lactate signal is maximal, then show this to be
mathematically equal to the product of kP and T1 eff. Further-
more, they show that an estimate for T1 eff can be obtained from
the width of the lactate curve at a specific height α. Although
they suggest it is sufficient to use a consistent value of α = 0.8,
we calculated α explicitly in each case to avoid incurring a non-
physical correlation between kP and T1.
Lactate–pyruvate peak ratio
The in vitro T1 eff is only affected by physical factors such as mag-
netic field and temperature. Since these factors are controlled
for, T1 eff is not expected to show a large variation. The above pa-
rameter β, which we re-name the L–P peak ratio, could therefore
be expected to correlate with LDH concentration, and as such
was investigated as a potential parameter of interest.
AUC ratio
The ratio of the lactate-to-pyruvate AUC has been shown by Hill
et al. to be independent of the shape of the pyruvate inflow (24),
making it an excellent candidate for analysis of in vivo data. If it is
assumed that only the pyruvate has an explicit input function
and that the concentration of both metabolites is zero at t = 0,
then using the two-way, two-site model the AUC ratio can be
shown to be proportional to kP. For in vitro data this ratio was cal-
culated in two ways: first taking the AUC ratio of the available
data (AUC data) and second fitting bi-exponential solutions ex-
trapolated back to t = 0 (AUC fit).
Time-to-peak measurements
Finally, we suggest a new approach that examines the time dif-
ference from the start of the lactate build up to its peak, as has
been used in DCE-MRI. Starting from the two-way model, the
rate equations can be solved analytically to find the time at
which the lactate reaches its maximum by differentiating the lac-
tate solution, and solving for t when this is zero. The time-to-
peak (TTP) is then given by
TTP ¼ 1
kP þ kL :ln 1þ T1 eff kP þ kPð Þf g
The TTP should show a roughly inverse correlation with LDH
concentration. A bi-exponential function was fitted to the time-
domain lactate data and extrapolated back to find the predicted
start time of the increase in lactate signal from zero. Schematic
diagrams of each of the models and model-free methods
described above are presented in Figure 1a–f.
In vivo imaging
In vivo analysis of pyruvate metabolism is complicated by the
flow of injected metabolites in the bloodstream, tissue diffusion
and cellular transport. For full modelling of this data, a pyruvate
inflow function (PIF) must be included to describe the large ini-
tial pyruvate peak as the injected bolus reaches the tissue of in-
terest. In the interest of simplicity, each of the four model
variants was fitted only to data from the pyruvate peak onwards,
which in each case occurred at the third data point. Each of the
model-free methods was implemented on the entire dataset. A
common way to approximate the PIF is to use a box-car or tra-
pezoidal function, and an alternative is to fit a piecewise integral
solution. The latter involves splitting the pyruvate profile into
two segments described by separate equations: the first for con-
stant pyruvate inflow, and the second describing signal decay
and conversion to lactate (19,34–36). Here we have used a Heav-
iside step function to incorporate a continuous PIF into the pyru-
vate two-way differential equation with the same characteristics
as a box-car function:
dP tð Þ
dt ¼ ki 1 11þe2 tteð Þ
 
þ kLL tð Þ  kPP tð Þ  ρP tð Þ
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where ki is the pyruvate flow rate and te is the time at which the
inflow ceases. We compared this to the piecewise one-way integral
model described by Zierhut et al. (19) in two ways: fixing te at the
peak of the pyruvate curve or fitting for it as an extra parameter.
Statistical analysis
The quantitative parameters derived using each method were
tested for their correlation with the known in vitro LDH concen-
tration. These correlations were generally linear. Both Pearson
(linear) and Spearman (rank) correlation coefficients and their
two-tailed p-values were calculated, so that it was possible to
compare all methods directly whilst making no assumptions
about the nature of the dependences. In order to determine
whether one analysis approach was significantly better than another,
Steiger’s z-test for dependent correlations was implemented pairwise
on the Pearson then Spearman coefficients produced by each
method, and the two-tailed p-values calculated (significance p <
0.05) (37). In addition, a simple linear regression model was applied
in each case to calculate the adjusted R2 values both with and
without a robust bi-square weighting function applied to the data.
The difference in R2 with and without the weighting, denoted the
‘instability’ factor, provides a crude indicator of howmuch the fit is
dominated by outliers and therefore how robust a particular method
may be. The mean, range and SD of T1 values obtained from all
phantoms taken together were also analysed for each quantitative
method to assess goodness of fit. Since T1 is expected to be highly
consistent in vitro, a large range and high SD suggests that a model
is not fully describing the data or is underparameterized.
To assess how well each model was able to fit the in vivo data, the
corrected Akaike information criteria (AICc) were calculated (38). The
AICc uses the minimized likelihood function values to examine how
well each model is able to describe the data, whilst imposing a pen-
alty for each extra free parameter to guard against overfitting; a low
AICc denotes higher model accuracy. The relative likelihood that
each model is correct as compared to the model with the lowest
AICc was then calculated. To investigate model-free parameters
in vivo, correlation coefficients and R2 values were again calcu-
lated; however because the enzyme activity was an unknown,
they were compared against kP values derived using the most
likely model with ROI or POI data as appropriate. The ROI and
POI results were combined when calculating correlation coeffi-
cients due to the small size of the dataset.
RESULTS
In vitro modelling
Thirty-three 15 ml phantoms containing 0 U (n = 2), 20 U (n = 5), 40
U (n = 6), 60 U (n = 6), 80 U (n = 6), 100 U (n = 5) and 120 U (n = 3)
of LDH enzyme were imaged in sets of three, for which representa-
tive images can be seen in Figure 2a. Ringing artefacts, noise spikes
and other interference were visible in some images; however, since
it was of particular interest to test the quantitative analysis
methods for robustness against such common artefacts, none of
the data was excluded. The quantitative parameters obtained with
each analysis method were tested for their correlation with the
known scale of phantom LDH concentrations. The two-tailed
p-values calculated from the Pearson and Spearman correlation
coefficients were all highly significant (p < 0.001).
The results of the analyses are summarized in Table 1. For the
model-based approaches, application of Steiger’s z-test to the
Pearson coefficients for the ROI data demonstrated the
ratiometric method to be significantly poorer than the other
three models, which were not found to be significantly different.
However, the POI data showed the one-way model to be worse
than the other methods tested. In both cases, the differential
Figure 1. Schematic diagrams for each of the models and model-free methods proposed. (a) Interactions accounted for in the two-way differential/
integral models where kP and kL are the forward and backward reaction rate constants respectively and ρ is the inverse of the effective spin–lattice
relaxation, T1 eff. (b) Interactions for one-way integral model. (c) Example metabolite time courses demonstrating the ratiometric model. (d) FmRα
approach and L–P ratio method. (e) Lactate-to-pyruvate AUC ratio. (f) Lactate TTP.
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Figure 2. Representative data from the in vitro study. (a) IDEAL spiral CSI axial images of pyruvate and lactate in three phantoms, displayed at 24 s
intervals. Phantoms contain 40, 0 and 20 U of LDH enzyme (clockwise from top); the colour bar shows arbitrary signal units scaled to the brightest point
in the time curve for each metabolite. (b) Pyruvate and lactate time courses (solid lines) extracted from the 40 U phantom using the ROI method and
fitted using the differential two-way kinetic model (dashed lines). (c) Correlation with LDH enzyme concentration of the forward reaction rate constants
kP derived from four model variants (differential, integral, ratiometric and one-way models). Note that the scale for kP varies between plots.
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and integral models are better able to constrain T1 compared to
the other three methods, which suggests that they are more
closely modelling the data. A fit with the differential model is
shown in Figure 2b. The variation in kP between the integral
and differential versions of the two-way model is a function of
the algorithm used for fitting the data, but this difference was
shown to be insignificant (p > 0.2). Despite the simplicity of
the FmRα approach, kP values obtained from the FmRα analysis
were not significantly different from those obtained by model-
ling methods, other than the ROI integral model.
In contrast, the model-free methods showed greater variation,
with the TTP proving to be significantly better, and the L–P ratio
significantly worse, than other methods tested. The AUC from the
extrapolated fits also performed well, being indistinguishable from
the modelling approaches. When p-values were calculated from
the Spearman coefficients, the results largely supported those from
the Pearson coefficients with the exception of the TTP, which per-
formed least well. Table 2 shows full significance matrices for both
ROI and POI data from the pairwise application of Steiger’s z-test.
The sensitivity of kP may be examined in terms of the offsets of
the fit lines at the origin. The cause of these offsets is twofold:
first there is a positive skew caused by the divergent kP values
produced at high LDH concentrations, and second sensitivity
limitations at very low concentrations cause an initial monotonic
but non-linear rise in kP with increasing LDH. The relative sensi-
tivity of each model to these features is characterized by the dif-
ference in the two correlation coefficients; they are accounted
for well by the Spearman coefficients, which allow regions of
monotonic non-linear increase, but will incur a penalty with the
Pearson coefficients, which enforce linearity.
In vivo modelling
Each of the four models tested in vitro were fitted to both ROI and
POI derived time-course data from four rats with subcutaneously
implanted tumours. An additional three models were tested which
incorporated a PIF. The AICc scores and the relative likelihood of
each model correctly describing the observed data were then cal-
culated; the results of this, along with the T1 mean, range and SD,
are shown in Table 3. The T1 values obtained were slightly higher
than those previously estimated in healthy rats of about 15 s, but
consistent with other rodent tumour T1 values (19,39). The in vivo
results were similar to those found in vitro, with the differential
and integral models statistically indistinguishable from each other,
but significantly more likely than the one-way or ratiometric
models to accurately describe the data. Models incorporating a PIF
were applied to a larger number of data points than the remaining
models to include data prior to the pyruvate peak. For this reason,
the relative likelihood values for the PIF models were calculated sep-
arately to compare just these three, as shown in Table 3.
The differential model with the Heaviside step PIF provided the
lowest AICc of the three, fitting the data significantly better than
the piecewise models. Interestingly, the penalty for allowing the
end of inflow time te to vary as an extra free parameter within
the piecewise model was greater than the improvement this
made to the fit. It has been stated by previous users of the model
that te should correspond to the injection length starting from t0
(19,35), which in the case of the rats was around 2 s. The fitted te
calculated here was 8–10 s, which corresponded to the pyruvate
peak time instead. For this reason, te was then fixed at the pyru-
vate peak time, as was the centre of the downslope for the Heav-
iside step function used in the differential model. Figure 3b shows
fits of the differential PIF model as compared with the fixed te
piecewise model to ROI time courses from one animal (Rat 1).
In the absence of a gold standard as a comparator, it was dif-
ficult to assess the model-free parameters in vivo. However the
differential model with a Heaviside step PIF was used as a surro-
gate standard, given its low AICc. Based on comparison with
these calculated kP values, the TTP significantly out-performed
the other approaches and the L–P ratio performed least well,
being the only method to produce no significant correlation
coefficients. The AUC also correlated very well with kP, with both
Table 1. Summary of the analysis for the in vitro data are shown by comparing the calculated exchange rate constants with the
known enzyme concentration. Calculations have been performed using both the ROI and POI approaches
ROI Pearson Spearman Adj. R2 Adj. R2 robust Instability T1 mean T1 range T1 SD
kP differential 0.950 0.984 0.900 0.917 0.017 52.4 13.2 3.04
kP integral 0.952 0.986 0.903 0.931 0.028 52.5 13.5 2.97
kP one-way 0.942 0.982 0.883 0.907 0.025 58.4 21.7 5.99
kP ratiometric 0.896 0.986 0.796 0.891 0.095 57.3 26.9 5.46
kP FmRα 0.920 0.981 0.842 0.923 0.082 47.7 21.9 4.36
L–P ratio 0.854 0.969 0.721 0.905 0.184 – – –
AUC data 0.877 0.966 0.761 0.945 0.184 – – –
AUC fit 0.916 0.974 0.833 0.944 0.110 – – –
TTP 0.971 0.964 0.940 0.946 0.006 – – –
POI
kP differential 0.925 0.982 0.852 0.946 0.094 53.8 12.4 3.75
kP integral 0.919 0.982 0.840 0.939 0.100 54.0 15.8 4.23
kP one-way 0.767 0.924 0.574 0.923 0.348 60.2 26.6 7.78
kP ratiometric 0.915 0.984 0.831 0.852 0.020 58.6 30.4 6.63
kP FmRα 0.922 0.981 0.846 0.942 0.096 46.4 21.8 4.81
L–P ratio 0.858 0.976 0.727 0.921 0.195 – – –
AUC data 0.880 0.971 0.766 0.926 0.160 – – –
AUC fit 0.898 0.976 0.801 0.943 0.142 – – –
TTP 0.963 0.964 0.926 0.921 0.005 – – –
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correlation coefficients having p < 0.005. Parameter maps for kP
were generated for each of the four rats and are shown in Figure 4:
in vivo parameter mappings derived from the model-based
methods were largely similar, and two representative examples
are shown using the one-way and two-way non-PIF integral models.
Unfortunately, many of the model-free parameter mapping
Table 2. Significance matrix for in vitro data from ROI data (top) and POI data (bottom). Matrix shows p-values from applying
Steiger’s z-test for comparing the relative strength of correlations pairwise to Pearson coefficients; the Pearson coefficients test
the correlation between quantitative parameters produced by each method, and known enzyme concentration. * indicates that
the better ranking (high 1–9 low) analysis method of the two is significantly so (significance level p < 0.05)
ROI analysis Pearson Raw rank kP integral kP one-way kP ratiometric kP FmRα L–P ratio AUC data AUC fit TTP
kP differential 0.9503 3 0.762 0.664 0.001* 0.075 0.001* 0.007* 0.098 0.156
kP integral 0.9518 2 – 0.604 0.000* 0.050* 0.000* 0.005* 0.075 0.183
kP one-way 0.9415 4 – 0.032* 0.402 0.011* 0.051 0.336 0.219
kP ratiometric 0.8956 7 – 0.380 0.322 0.643 0.539 0.001*
kP FmRα 0.9201 5 – 0.000* 0.010* 0.722 0.010*
L–P ratio 0.8541 9 – 0.078 0.000* 0.000*
AUC data 0.8766 8 – 0.000* 0.000*
AUC fit 0.9158 6 – 0.007*
TTP 0.9705 1 –
POI analysis
kP differential 0.9254 2 0.206 0.000* 0.640 0.753 0.003* 0.073 0.173 0.054
kP integral 0.919 4 – 0.000* 0.860 0.763 0.007* 0.129 0.303 0.035*
kP one-way 0.7666 9 – 0.002* 0.000* 0.048* 0.026* 0.003* 0.000*
kP ratiometric 0.9147 5 – 0.780 0.173 0.375 0.647 0.020*
kP FmRα 0.9223 3 – 0.000* 0.024* 0.103 0.048*
L–P ratio 0.8575 8 – 0.103 0.001* 0.001*
AUC data 0.8795 7 – 0.074 0.003*
AUC fit 0.8983 6 – 0.010*
TTP 0.9633 1 –
Table 3. Summary of statistical analysis from calculating the AICc for each model, separately fitted to ROI and POI data from four
rats with subcutaneously implanted tumours. The relative likelihoods for models incorporating a PIF were calculated separately
against each other. The lowest section shows correlation coefficients for model-free parameters against kP values from the differ-
ential Heaviside step PIF model. * p < 0.05; ** p < 0.001
ROI Average AICc Relative likelihood T1 mean T1 range T1 SD
kP differential 368.9 0.257 25.7 7.51 2.78
kP integral 367.5 1 25.4 7.60 2.90
kP one-way 403.3 2.95 × 10
16 23.2 5.98 2.26
kP ratiometric 388.8 5.87 × 10
10 27.1 8.54 3.03
kP differential, PIF 469.0 1 24.6 6.90 2.61
kP piecewise, fixed te PIF 495.9 2.12 × 10
12 22.2 5.71 2.24
kP piecewise, variable te PIF 499.2 2.12 × 10
12 22.2 5.78 2.28
POI
kP differential 436.1 1 25.0 4.75 1.83
kP integral 436.2 0.880 25.2 4.84 1.89
kP one-way 449.5 1.51 × 10
6 22.8 5.18 1.97
kP ratiometric 469.0 5.28 × 10
15 27.6 2.47 0.91
kP differential, PIF 527.8 1 23.9 4.59 1.73
kP piecewise, fixed te PIF 533.7 2.97 × 10
3 22.5 5.82 2.13
kP piecewise, variable te PIF 536.4 1.90 × 10
4 22.0 5.53 2.15
Combined ROI and POI Pearson Spearman Adj. R2 Adj. R2 robust
kP FmRα 0.797* 0.714 0.574 0.497
L–P ratio 0.636 0.548 0.305 0.637
AUC 0.888* 0.905* 0.754 0.733
TTP 0.970** 1.00** 0.930 0.920
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methods were very sensitive to noise in regions of low lactate, ren-
dering them difficult to interpret, which is an inherent limitation of
some of these more simplified approaches. A visual inspection of
the two sets shows that both models were able to distinguish the
implanted tumours from normal tissue; however, the two-way maps
appeared to better highlight the full tumour and offered higher
contrast-to-noise ratio, showing increased sensitivity over the
one-way model. kP values were capped at 0.25 s
1, a value cho-
sen to be suitably above those previously reported in rat
tumours (~0.1 s1) (28); only one rat (Rat 4) had an area of very
high activity greater than this. The mean tumour kP and range
were both higher with the two-way than the one-way model,
and in general the kP maps demonstrated significant intra-
tumour heterogeneity.
DISCUSSION
Metabolic imaging with hyperpolarized 13C-labelled molecules is
an emerging clinical tool to non-invasively detect real-time meta-
bolism. In order to utilize this dynamic data – either as a research
technique or ultimately as a clinical tool – mathematical analysis
methods are required that are sensitive to the small changes in
metabolism that occur during tumour growth and following treat-
ment, whilst being insensitive to noise and artefacts. Many of the
approaches used to analyse the metabolism of hyperpolarized py-
ruvate are analogous to the methods used in other areas of MRI
research (such as DCE-MRI), as well as those used with PET. We
have performed a comprehensive analysis of the main quantita-
tive techniques used to analyse hyperpolarized data, as well as
some novel approaches, with the aim of determining which are
the most appropriate as research tools and which may have
potential for clinical application in the future. Here we have used
imaging data, rather than spectroscopic data, as this will be more
applicable to patient studies, and have compared two methods of
extracting the dynamic time-course data from these images.
The approaches we studied can be divided into two groups:
model-based and simpler model-free analyses. Of the four kinetic
model variants, the differential and integral two-way models per-
formed best, showing strong correlation with in vitro LDH enzyme
concentration and producing the most accurate modelling in vivo
(as determined by a low AICc). Furthermore, the T1 values produced
by these models, which we expect to be constant in vitro, had the
smallest ranges and SDs of those tested, implying good parameter-
ization. The one-way model is a very popular approach because it
allows for the use of Michaelis–Menten kinetics in order to solve
for real, as opposed to apparent, reaction rate constants. However,
this requires an assumption that is not fulfilled by the hyperpolarized
exchange reaction: that the reaction has reached chemical equilib-
rium (40). The one-way model was found to be unstable at higher
Figure 3. In vivo data from a rat (Rat 1) with a subcutaneous implanted mammary adenocarcinoma. (a) Proton anatomical reference image and
hyperpolarized 13C-pyruvate and 13C-lactate images at t = 20 s; colour bar in arbitrary signal units. (b) Pyruvate and lactate time courses (solid lines)
extracted from the thresholded tumour ROI and fits (dashed lines) from the differential kinetic model with a Heaviside step PIF (left) and the fixed
te piecewise model (right) for comparison.
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enzyme concentrations within the physiological range, producing
divergent kP values almost three times higher than those given by
the two-way models (Fig. 2c). This divergence was also seen in some
of the in vivo data sets (Fig. 4, Rat 4), and is likely to be a conse-
quence of the approximation kL = 0, which becomes less valid with
increasing enzyme activity or in the presence of large pools of lactate
that are freely exchanging with the pyruvate. A previous comparative
study by Harrison et al. (41) demonstrated the shortcomings of the
one-waymodel by showing that results from fitting to hyperpolarized
data were incompatible with those from mass spectrometry data.
This suggests an inconsistency between the model and the under-
lying biology; the breakdown of the model at high enzyme activity
that we have observed here provides further evidence against the
use of the one-way model.
We also examined the effect of explicitly modelling the pyruvate
inflow within both the differential and integral (piecewise) models.
Kazan et al. suggest modelling the PIF with a gamma-variate func-
tion, which, although an excellent descriptor for the flow profile,
requires accurate measurement of the arterial input function either
with an invasive arterial line, or by image acquisition from a large
vessel, which may be difficult to obtain from human hyperpolarized
data (36). We therefore looked at incorporating simpler functions.
From calculations of the AICc, the differential model with a
Heaviside step PIF was significantly more likely to correctly describe
the data than either variant of the piecewise model. The fitted pyru-
vate inflow end-time te in this model correlated poorly with the
measured injection length; this mismatch is indicative of the diffi-
culty in fitting theoretical arterial input functions to hyperpolarized
data with a low SNR and temporal resolution. Complicated inflow
functions introduce several additional free parameters, which overfit
noisy data and increase the error of the derived rate constants. With
the current resolution limitations for clinical hyperpolarized imag-
ing, simple approximations for pyruvate inflow, such as those used
in this study, are therefore required.
The above methodologies are desirable when accurate fitting
is required for research purposes; however, kinetic modelling can
be computationally intensive and time consuming. We tested
four model-free methods as candidates for providing simple,
robust parameters that are fully representative of the metabolic
exchange reaction. Such approaches may allow easy intra-patient
and inter-patient comparison across clinical sites. The FmRα
method described by Pagès and Kuchel (23) provided a better
correlation with LDH concentration and tighter constraints on T1
than two of the modelling methods. However, in our study it
was necessary to calculate α explicitly in each case, rather than
Figure 4. Functional parameter mapping in four rats with subcutaneous mammary adenocarcinomas demonstrating intratumoral heterogeneity. (a)
Grey scale anatomical proton images showing the outline of the implanted tumours defining the ROI (green) and POI (white cross) used for modelling.
(b) False-colour functional maps of kP calculated using the one-way integral model superimposed over the grey scale anatomical imaging. (c) Similar
colour maps using a two-way integral model. The maximum kP has been limited to 0.25 s
1 in both cases.
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using a constant value as suggested by the authors, to produce
realistic results. Simpler still, and producing similar statistical
results, is the AUC ratio described by Hill et al. (24), which is inde-
pendent of the PIF. The lactate-to-pyruvate ratio at the time of
maximum lactate signal was consistently the poorest method
for describing the data. The final approach using TTP showed
the strongest correlation with enzyme concentration in vitro of
any analysis and the strongest correlation with kP values derived
using the differential PIF model in vivo of any model-free method.
The small size of the in vivo dataset means it is not possible to
claim significance of the TTP over the AUC, and so further testing
of these two methods on larger in vivo data sets is required.
Nonetheless, these preliminary results along with the in vitro
results suggest that the TTP may prove to be a very robust quan-
titative marker that is able to provide an equivalent assessment of
metabolism to fitting a full PIF kinetic model.
Finally, we looked at two methods for extracting dynamic time-
course data from the images and assessed them for their effect
on quantification. Data extracted using the ROI method provided
universally stronger correlations with the in vitro enzyme concen-
trations than the POI method, although this was not significant in
the majority of cases. Averaging results over a tumour ROI may
provide a more sensitive measure of metabolic change in that re-
gion which is robust to experimental noise; however, it tells
nothing of the local heterogeneity nor does it allow for tumours
outside the region to be detected in the way that pixel-by-pixel
analysis could. Furthermore, determining the anatomical limits
of a tumour is subjective, and therefore difficult to reproduce ac-
curately, even if performed by the same operator using the same
dataset (42,43). Our findings suggest that extracting data from a
single POI is sufficiently robust to provide a metric that reports
on the whole area, and may provide a simple and reproducible
method for analysing the data objectively over time. This ap-
proach is analogous to the SUVmax used routinely in the analysis
of clinical PET data. Under normal conditions, the POI
(representing the highest lactate concentration over time) will
lie within the boundaries of the tumour. Although unlikely, theo-
retically the POI could lie outside the tumour margin if it was so
poorly vascularized that the time required to perfuse the tumour
was long compared with the half-life of the polarized pyruvate
signal, or if the systemic lactate level was very markedly elevated.
Since single-pixel analysis was shown to be sufficiently robust,
parameter mapping of kP was performed in the rats. This showed
marked intratumoral heterogeneity, with some areas of low
exchange within the tumours and regions of high activity extend-
ing beyond the tumour boundary. Due to the spatial resolution of
the 13C images, it is not possible to determine whether these find-
ings are due to artefacts from partial voluming or whether there is
underlying biological heterogeneity due to changes in metabolism
or vascularity, although a highly heterogeneous vasculature is a
known feature of the subcutaneous tumour type studied here (44).
The rate constant kP is generally considered to be the gold
standard for quantification of hyperpolarized data, but several
of the simpler non-model-based approaches used here appeared
to provide a good approximation to the reaction. A good probe
for tumour biology should be repeatable, reproducible, quantita-
tive, highly sensitive and highly specific. The results of this study
show that kP is a robust biomarker of LDH activity. However, at
low LDH concentrations the modelling is more susceptible to
noise, and at high LDH concentrations greater divergence was
demonstrated, which may relate to undersampling. Importantly,
this work has shown that these modelling methods performed
well in the physiological range, and further research is required
from human studies to validate this. Variation in kP may occur
secondary to other factors such as SNR, which is dependent on
polarization (45,46), pyruvate concentration (35) and imaging
protocol (47). Therefore the optimization and standardization of
each of these is an important step for multi-centre comparison,
or if kP is to be considered as a clinical tool.
In conclusion, for accurate kinetic analysis of the hyperpolarized
pyruvate–lactate exchange reaction in vivo, the two-way differential
model with a Heaviside step PIF centred on the pyruvate peak was
best able to characterize the data with the fewest free parameters.
If the data prior to the pyruvate peak is not included in the analysis,
the two-way differential and integral models performed equally well
andwere significantly better than the one-waymodel in thepresence
of high enzyme activity or when applied to the pixel-by-pixel analysis.
As a simple parameter for clinical quantification of hyperpolarized
imagingdata, theTTPperformedbest both in vitro and in vivo, providing
excellent correlation with model-derived kP values. Extracting data
from an averaged ROI may provide the most sensitivity to small
changes in metabolism; however, the POI approach is sufficiently
robust to be applied pixel-by-pixel, allowing tumour heterogeneity
to be probed. This work provides a basis for analysing data from
future human trials in hyperpolarized 13C imaging.
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